Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025)

AVITA Medical's Cash from Financing Activities history spans 7 years, with the latest figure at $248000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 75.71% year-over-year to $248000.0; the TTM value through Dec 2025 reached $14.9 million, up 325.77%, while the annual FY2025 figure was $14.9 million, 325.77% up from the prior year.
  • Cash from Financing Activities reached $248000.0 in Q4 2025 per RCEL's latest filing, down from $13.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $64.0 million in Q1 2021 to a low of -$64.1 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $3.3 million, with a median of $579500.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 98404.62% in 2021, then plummeted 206745.16% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $3000.0 in 2021, then skyrocketed by 29866.67% to $899000.0 in 2022, then soared by 4286.21% to $39.4 million in 2023, then plummeted by 97.41% to $1.0 million in 2024, then plummeted by 75.71% to $248000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Cash from Financing Activities are $248000.0 (Q4 2025), $13.8 million (Q3 2025), and $559000.0 (Q2 2025).